Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brest Cancer
Proteomics company enrolls participants from three sites in breast cancer trial
July 21st, 2005
Power3 Medical Products, Inc., (PWRM) announced that to date it has enrolled 137 participants from three participating locations - the Clinical Research Center of Houston, Obstetrical and Gynecological Associates (OGA), Mercy Women's Center in Oklahoma City and NYU Medical Center - in its multisite clinical validation study for the early detection of breast cancer. The validation study involves the collection of nipple aspirate fluid (NAF) and blood serum samples from several hundred women. The company expects enrollment to continue without any changes to sites or primary investigators. The collection of nipple aspirate fluid is a noninvasive...
Source: Women's Health Weekly (2005-07-21)
|
